Skip to main content

Neighborhood Disadvantage Tied to Shorter Breast Cancer-Specific Survival

Medically reviewed by Carmen Pope, BPharm. Last updated on April 21, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, April 19, 2024 -- Neighborhood disadvantage is associated with shorter breast cancer-specific survival, according to a study published online April 18 in JAMA Network Open.

Neha Goel, M.D., M.P.H., from the University of Miami Miller School of Medicine, and colleagues examined whether neighborhood disadvantage is associated with shorter breast cancer-specific survival in a national retrospective cohort study involving patients with breast cancer diagnosed from 2013 to 2018. Data were included for 350,824 patients with breast cancer.

Overall, 25.0 and 14.9 percent of patients lived in the most advantaged and most disadvantaged neighborhoods, respectively. A larger number of non-Hispanic White patients lived in advantaged neighborhoods (76.2 percent), while the highest proportion of non-Hispanic Black and Hispanic patients was seen in disadvantaged neighborhoods (30.9 and 19.5 percent, respectively). Compared with the most advantaged neighborhoods, the most disadvantaged neighborhoods had the highest risk for mortality in a breast cancer-specific survival analysis (hazard ratio, 1.43).

"To address these residual disparities associated with neighborhood disadvantage, future research must take a translational epidemiologic approach to focus on biological and nonbiological factors through which the built environment, above the beyond individual-level factors, may influence outcomes," the authors write. "This approach to research has the potential to advance precision medicine in oncology by bringing neighborhood disadvantage into consideration when risk-stratifying vulnerable populations and to develop cancer control interventions to overcome breast cancer disparities."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States

THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...

Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening

WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.